Development of orphan coenzyme q10 liquid formulations for pediatric patiens

Autores
Estevez, Pablo Nicolas; Tripodi, Valeria Paula; Boscolo, O.; Chiappetta, Diego Andrés; Buontempo, Fabian; Lucangioli, Silvia Edith
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Coenzyme Q10 (CoQ10) deficiency is involved in cardiomyopathies and degenerative muscle and neuronal diseases. Most patients with these deficiencies have shown clinical improvement with oral CoQ10 supplementation especially in pediatric patients (1). In the case of the active drugs with physicochemical characteristics of poor aqueous solubility, high hydrophobicity and consequently poor absorption like CoQ10, various formulation strategies can be used (2). The aim of this study was to develop two oil solutions, one of them with the addition of vitamin E and one oil-in-water emulsion of CoQ10 and study the chemical stability of CoQ10 by microHPLC in the proposed extemporaneous formulations stored at room temperature over 110 days. Two CoQ10 oil solutions (50 mg/ml) were prepared by solubilising CoQ10 powder in soybean oil at 40°C. It was then added 0.05 % w/v of Vitamin E to one of the oil solutions. The vehicle of the O/W emulsion was prepared with xanthan gum 0.25% w/v, soybean oil 45%, syrup 30%, distilled water 23.85%, methylparaben 0.08%, propylparaben 0.02%, sodium saccharin 0.3% and orange essence 0.5%. The final CoQ10 concentration of the O/W emulsion was 20 mg/ml. All the trial formulations were stored in amber glass vials and kept at controlled room temperature (25°C). All samples were stored at 25°C. CoQ10 content of each formulation was analyzed in duplicate by MicroHPLC at 0, 3, 6, 15, 30, 60 and 110 days (Figure). All formulations stayed stable at 25°C during the 110 days of the study. However, the oil solutions showed significant variations of CoQ10 concentrations (up to 26%), whereas the O/W emulsion stayed on a 10% range. At the end of the study (day 110), the amount of CoQ10 in all three formulations was between 97 and 103% (Table). Significant content variations through all the study period for the oil solutions were founded, probably due to the vehicle chosen. This may potentially modify the amount of CoQ10 delivered to the patient, making them not suitable for pediatric practice in which more reliable dose adjustment is required. Moreover, no differences were found between the two oil solutions, with and without vitamin E. The O/W emulsion content instead was not significantly affected, making it the formulation of choice for pediatric administration of CoQ10. Stability data at controlled room temperature is very important since there is no need of using special storage conditions. In conclusion, the CoQ10 emulsion can be stored for at least 110 days at 25°C and it has proven to be safer when narrow dose adjustment is required.
Fil: Estevez, Pablo Nicolas. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina
Fil: Tripodi, Valeria Paula. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Boscolo, O.. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina
Fil: Chiappetta, Diego Andrés. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Buontempo, Fabian. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina
Fil: Lucangioli, Silvia Edith. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina
Materia
Coenzyme Q10
Orphan Formulation
Pediatrics
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/1914

id CONICETDig_6c0c4d28190edf9bb57b6088714a735f
oai_identifier_str oai:ri.conicet.gov.ar:11336/1914
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Development of orphan coenzyme q10 liquid formulations for pediatric patiensEstevez, Pablo NicolasTripodi, Valeria PaulaBoscolo, O.Chiappetta, Diego AndrésBuontempo, FabianLucangioli, Silvia EdithCoenzyme Q10Orphan FormulationPediatricshttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Coenzyme Q10 (CoQ10) deficiency is involved in cardiomyopathies and degenerative muscle and neuronal diseases. Most patients with these deficiencies have shown clinical improvement with oral CoQ10 supplementation especially in pediatric patients (1). In the case of the active drugs with physicochemical characteristics of poor aqueous solubility, high hydrophobicity and consequently poor absorption like CoQ10, various formulation strategies can be used (2). The aim of this study was to develop two oil solutions, one of them with the addition of vitamin E and one oil-in-water emulsion of CoQ10 and study the chemical stability of CoQ10 by microHPLC in the proposed extemporaneous formulations stored at room temperature over 110 days. Two CoQ10 oil solutions (50 mg/ml) were prepared by solubilising CoQ10 powder in soybean oil at 40°C. It was then added 0.05 % w/v of Vitamin E to one of the oil solutions. The vehicle of the O/W emulsion was prepared with xanthan gum 0.25% w/v, soybean oil 45%, syrup 30%, distilled water 23.85%, methylparaben 0.08%, propylparaben 0.02%, sodium saccharin 0.3% and orange essence 0.5%. The final CoQ10 concentration of the O/W emulsion was 20 mg/ml. All the trial formulations were stored in amber glass vials and kept at controlled room temperature (25°C). All samples were stored at 25°C. CoQ10 content of each formulation was analyzed in duplicate by MicroHPLC at 0, 3, 6, 15, 30, 60 and 110 days (Figure). All formulations stayed stable at 25°C during the 110 days of the study. However, the oil solutions showed significant variations of CoQ10 concentrations (up to 26%), whereas the O/W emulsion stayed on a 10% range. At the end of the study (day 110), the amount of CoQ10 in all three formulations was between 97 and 103% (Table). Significant content variations through all the study period for the oil solutions were founded, probably due to the vehicle chosen. This may potentially modify the amount of CoQ10 delivered to the patient, making them not suitable for pediatric practice in which more reliable dose adjustment is required. Moreover, no differences were found between the two oil solutions, with and without vitamin E. The O/W emulsion content instead was not significantly affected, making it the formulation of choice for pediatric administration of CoQ10. Stability data at controlled room temperature is very important since there is no need of using special storage conditions. In conclusion, the CoQ10 emulsion can be stored for at least 110 days at 25°C and it has proven to be safer when narrow dose adjustment is required.Fil: Estevez, Pablo Nicolas. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; ArgentinaFil: Tripodi, Valeria Paula. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Boscolo, O.. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; ArgentinaFil: Chiappetta, Diego Andrés. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Buontempo, Fabian. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; ArgentinaFil: Lucangioli, Silvia Edith. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; ArgentinaElsevier Science2013-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/vnd.openxmlformats-officedocument.wordprocessingml.documentapplication/pdfhttp://hdl.handle.net/11336/1914Estevez, Pablo Nicolas; Tripodi, Valeria Paula; Boscolo, O.; Chiappetta, Diego Andrés; Buontempo, Fabian; et al.; Development of orphan coenzyme q10 liquid formulations for pediatric patiens; Elsevier Science; European Journal Of Pharmaceutical Sciences; 8-2013; 69-700928-0987engCongreso; 5th International BBBB Conference; The European Federation for Pharmaceutical Sciences;2013info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:57:33Zoai:ri.conicet.gov.ar:11336/1914instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:57:34.132CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Development of orphan coenzyme q10 liquid formulations for pediatric patiens
title Development of orphan coenzyme q10 liquid formulations for pediatric patiens
spellingShingle Development of orphan coenzyme q10 liquid formulations for pediatric patiens
Estevez, Pablo Nicolas
Coenzyme Q10
Orphan Formulation
Pediatrics
title_short Development of orphan coenzyme q10 liquid formulations for pediatric patiens
title_full Development of orphan coenzyme q10 liquid formulations for pediatric patiens
title_fullStr Development of orphan coenzyme q10 liquid formulations for pediatric patiens
title_full_unstemmed Development of orphan coenzyme q10 liquid formulations for pediatric patiens
title_sort Development of orphan coenzyme q10 liquid formulations for pediatric patiens
dc.creator.none.fl_str_mv Estevez, Pablo Nicolas
Tripodi, Valeria Paula
Boscolo, O.
Chiappetta, Diego Andrés
Buontempo, Fabian
Lucangioli, Silvia Edith
author Estevez, Pablo Nicolas
author_facet Estevez, Pablo Nicolas
Tripodi, Valeria Paula
Boscolo, O.
Chiappetta, Diego Andrés
Buontempo, Fabian
Lucangioli, Silvia Edith
author_role author
author2 Tripodi, Valeria Paula
Boscolo, O.
Chiappetta, Diego Andrés
Buontempo, Fabian
Lucangioli, Silvia Edith
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Coenzyme Q10
Orphan Formulation
Pediatrics
topic Coenzyme Q10
Orphan Formulation
Pediatrics
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Coenzyme Q10 (CoQ10) deficiency is involved in cardiomyopathies and degenerative muscle and neuronal diseases. Most patients with these deficiencies have shown clinical improvement with oral CoQ10 supplementation especially in pediatric patients (1). In the case of the active drugs with physicochemical characteristics of poor aqueous solubility, high hydrophobicity and consequently poor absorption like CoQ10, various formulation strategies can be used (2). The aim of this study was to develop two oil solutions, one of them with the addition of vitamin E and one oil-in-water emulsion of CoQ10 and study the chemical stability of CoQ10 by microHPLC in the proposed extemporaneous formulations stored at room temperature over 110 days. Two CoQ10 oil solutions (50 mg/ml) were prepared by solubilising CoQ10 powder in soybean oil at 40°C. It was then added 0.05 % w/v of Vitamin E to one of the oil solutions. The vehicle of the O/W emulsion was prepared with xanthan gum 0.25% w/v, soybean oil 45%, syrup 30%, distilled water 23.85%, methylparaben 0.08%, propylparaben 0.02%, sodium saccharin 0.3% and orange essence 0.5%. The final CoQ10 concentration of the O/W emulsion was 20 mg/ml. All the trial formulations were stored in amber glass vials and kept at controlled room temperature (25°C). All samples were stored at 25°C. CoQ10 content of each formulation was analyzed in duplicate by MicroHPLC at 0, 3, 6, 15, 30, 60 and 110 days (Figure). All formulations stayed stable at 25°C during the 110 days of the study. However, the oil solutions showed significant variations of CoQ10 concentrations (up to 26%), whereas the O/W emulsion stayed on a 10% range. At the end of the study (day 110), the amount of CoQ10 in all three formulations was between 97 and 103% (Table). Significant content variations through all the study period for the oil solutions were founded, probably due to the vehicle chosen. This may potentially modify the amount of CoQ10 delivered to the patient, making them not suitable for pediatric practice in which more reliable dose adjustment is required. Moreover, no differences were found between the two oil solutions, with and without vitamin E. The O/W emulsion content instead was not significantly affected, making it the formulation of choice for pediatric administration of CoQ10. Stability data at controlled room temperature is very important since there is no need of using special storage conditions. In conclusion, the CoQ10 emulsion can be stored for at least 110 days at 25°C and it has proven to be safer when narrow dose adjustment is required.
Fil: Estevez, Pablo Nicolas. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina
Fil: Tripodi, Valeria Paula. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Boscolo, O.. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina
Fil: Chiappetta, Diego Andrés. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Buontempo, Fabian. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina
Fil: Lucangioli, Silvia Edith. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquimica. Departamento de Tecnologia Farmaceutica; Argentina
description Coenzyme Q10 (CoQ10) deficiency is involved in cardiomyopathies and degenerative muscle and neuronal diseases. Most patients with these deficiencies have shown clinical improvement with oral CoQ10 supplementation especially in pediatric patients (1). In the case of the active drugs with physicochemical characteristics of poor aqueous solubility, high hydrophobicity and consequently poor absorption like CoQ10, various formulation strategies can be used (2). The aim of this study was to develop two oil solutions, one of them with the addition of vitamin E and one oil-in-water emulsion of CoQ10 and study the chemical stability of CoQ10 by microHPLC in the proposed extemporaneous formulations stored at room temperature over 110 days. Two CoQ10 oil solutions (50 mg/ml) were prepared by solubilising CoQ10 powder in soybean oil at 40°C. It was then added 0.05 % w/v of Vitamin E to one of the oil solutions. The vehicle of the O/W emulsion was prepared with xanthan gum 0.25% w/v, soybean oil 45%, syrup 30%, distilled water 23.85%, methylparaben 0.08%, propylparaben 0.02%, sodium saccharin 0.3% and orange essence 0.5%. The final CoQ10 concentration of the O/W emulsion was 20 mg/ml. All the trial formulations were stored in amber glass vials and kept at controlled room temperature (25°C). All samples were stored at 25°C. CoQ10 content of each formulation was analyzed in duplicate by MicroHPLC at 0, 3, 6, 15, 30, 60 and 110 days (Figure). All formulations stayed stable at 25°C during the 110 days of the study. However, the oil solutions showed significant variations of CoQ10 concentrations (up to 26%), whereas the O/W emulsion stayed on a 10% range. At the end of the study (day 110), the amount of CoQ10 in all three formulations was between 97 and 103% (Table). Significant content variations through all the study period for the oil solutions were founded, probably due to the vehicle chosen. This may potentially modify the amount of CoQ10 delivered to the patient, making them not suitable for pediatric practice in which more reliable dose adjustment is required. Moreover, no differences were found between the two oil solutions, with and without vitamin E. The O/W emulsion content instead was not significantly affected, making it the formulation of choice for pediatric administration of CoQ10. Stability data at controlled room temperature is very important since there is no need of using special storage conditions. In conclusion, the CoQ10 emulsion can be stored for at least 110 days at 25°C and it has proven to be safer when narrow dose adjustment is required.
publishDate 2013
dc.date.none.fl_str_mv 2013-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/1914
Estevez, Pablo Nicolas; Tripodi, Valeria Paula; Boscolo, O.; Chiappetta, Diego Andrés; Buontempo, Fabian; et al.; Development of orphan coenzyme q10 liquid formulations for pediatric patiens; Elsevier Science; European Journal Of Pharmaceutical Sciences; 8-2013; 69-70
0928-0987
url http://hdl.handle.net/11336/1914
identifier_str_mv Estevez, Pablo Nicolas; Tripodi, Valeria Paula; Boscolo, O.; Chiappetta, Diego Andrés; Buontempo, Fabian; et al.; Development of orphan coenzyme q10 liquid formulations for pediatric patiens; Elsevier Science; European Journal Of Pharmaceutical Sciences; 8-2013; 69-70
0928-0987
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Congreso; 5th International BBBB Conference; The European Federation for Pharmaceutical Sciences;2013
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/vnd.openxmlformats-officedocument.wordprocessingml.document
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science
publisher.none.fl_str_mv Elsevier Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613721360433152
score 13.070432